The Law Offices of Frank R. Cruz announces an investigation of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On July 22, 2024, Allarity disclosed that it had received a Wells Notice from the U.S. Securities and Exchange Commission relating to the Company’s statements regarding meetings with the U.S. Food and Drug Administration about the Company’s NDA for its drug, Dovitnib, which was submitted in 2021. Three of Allarity’s former officers also received Wells Notices, wherein the SEC Staff stated it “has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws.”

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Allarity securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723376111/en/